- Home
- FDS vs MDGL Comparison
FDS vs MDGL Comparison
Compare FDS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDS | MDGL |
|---|---|---|
| Founded | 1978 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 12.5B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | FDS | MDGL |
|---|---|---|
| Price | $289.99 | $607.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $316.30 | ★ $580.77 |
| AVG Volume (30 Days) | ★ 838.0K | 298.4K |
| Earning Date | 12-18-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 12.60 | N/A |
| EPS | ★ 15.72 | N/A |
| Revenue | ★ $2,360,702,000.00 | $740,640,000.00 |
| Revenue This Year | $6.43 | $435.63 |
| Revenue Next Year | $5.34 | $52.56 |
| P/E Ratio | $18.51 | ★ N/A |
| Revenue Growth | 5.88 | ★ 864.21 |
| 52 Week Low | $250.50 | $265.00 |
| 52 Week High | $493.00 | $609.98 |
Technical Indicators
Market Signals| Indicator | FDS | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 65.63 |
| Support Level | $268.26 | $535.33 |
| Resistance Level | $295.43 | $609.98 |
| Average True Range (ATR) | 8.77 | 20.31 |
| MACD | 0.19 | 0.28 |
| Stochastic Oscillator | 57.69 | 84.71 |
Price Performance
Historical ComparisonAbout FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.